Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment
Digisha Trivedi,Pamela Landsman‐Blumberg,Theodore Darkow,David M. Smith,Donna McMorrow,C. Daniel Mullins-2014-10-01-Journal of Managed Care Pharmacy
38
TL;DRAbstract
Among second-line TKI-treated CML patients, dasatinib patients had significantly higher adherence and lower discontinuation rates compared with patients receiving second-line nilotinib.
Chat with Paper
AI Agents for this Paper
Among second-line TKI-treated CML patients, dasatinib patients had significantly higher adherence and lower discontinuation rates compared with patients receiving second-line nilotinib.
Keywords
NilotinibMedicineDasatinibDiscontinuationTyrosine-kinase inhibitorInternal medicineImatinibMyeloid leukemia
Chat
Click to start Chat